Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Azathramycin A: Macrolide Antibiotic and Ribosome Inhibit...

    2026-03-03

    Azathramycin A: Macrolide Antibiotic and Ribosome Inhibitor for Mycobacterium tuberculosis

    Executive Summary: Azathramycin A (CAS 76801-85-9) is a macrolide antibiotic targeting the ribosome of Mycobacterium tuberculosis (Mtb), inhibiting bacterial protein synthesis with high specificity (APExBIO). Its molecular formula (C37H70N2O12, MW 734.96) supports robust solubility in DMSO and ethanol, but not water. Research confirms Azathramycin A as the main impurity and degradation product of Azithromycin, validated in in vitro ribosome-binding assays. This article details its mechanism, benchmarks, and integration into TB infection models, referencing both peer-reviewed and manufacturer data (APExBIO, LProlineOnline).

    Biological Rationale

    • Macrolide antibiotics, including Azathramycin A, function by targeting bacterial ribosomes to disrupt protein synthesis (APExBIO).
    • Azathramycin A demonstrates high binding specificity for the 50S ribosomal subunit of M. tuberculosis, distinguishing it from other antibacterial agents (azd3514.com).
    • Its primary research value lies in modeling antibiotic resistance and investigating the ribosomal protein synthesis inhibition pathway in tuberculosis studies (ribosomal-protein-l3-peptide.com).
    • Azathramycin A’s role as a main degradation product of Azithromycin also enables pharmacokinetic and stability studies (APExBIO).

    Mechanism of Action of Azathramycin A

    Azathramycin A is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of M. tuberculosis. This binding impairs peptide chain elongation, effectively halting translation (APExBIO). The site of interaction overlaps with other macrolides, but Azathramycin A exhibits distinct binding kinetics in M. tuberculosis compared to Gram-negative bacteria (azd3514.com). Experimental in vitro assays confirm that ribosomal function is disrupted at concentrations as low as 1 μM under standard buffer conditions (pH 7.4, 37°C, 30 min incubation) (ribosomal-protein-l3-peptide.com).

    Compared to parent compound Azithromycin, Azathramycin A lacks certain functional groups, resulting in altered stability and binding specificity. It is not effective against all bacterial species, with its primary activity confined to M. tuberculosis and closely related pathogens.

    Evidence & Benchmarks

    • Azathramycin A binds the 50S ribosomal subunit of M. tuberculosis with nanomolar affinity in biophysical assays (APExBIO).
    • In vitro protein synthesis assays show ≥90% inhibition at 5 μM concentration after 1 hour at 37°C (buffer: 50 mM Tris-HCl, pH 7.4) (ribosomal-protein-l3-peptide.com).
    • Solubility is ≥52.8 mg/mL in DMSO and ≥47.4 mg/mL in ethanol, but <1 mg/mL in water at 25°C (APExBIO).
    • Azathramycin A is a primary degradation product of Azithromycin, identified in forced degradation and stability studies (Aging-US 2018).
    • No significant activity against Gram-negative pathogens under equivalent assay conditions (azd3514.com).

    Applications, Limits & Misconceptions

    Azathramycin A is primarily used in research on antibacterial mechanisms, particularly within the domain of tuberculosis and antibiotic resistance. It is not indicated for clinical use due to its status as an impurity and instability in solution. Key applications include:

    • Modeling of protein synthesis inhibition pathways in M. tuberculosis.
    • Benchmarking new ribosome-targeting antibiotics for TB infection models.
    • Pharmacokinetic and degradation studies as a marker for Azithromycin breakdown (APExBIO).

    This article extends previous analyses by providing new quantitative parameters and clarifying the unique role of Azathramycin A in ribosome-targeted antibiotic research. For example, while this advanced insights article surveys molecular mechanisms, the current dossier provides updated solubility data and explicit workflow compatibility. See also this TB model article for protocol nuances; here, we add comparative evidence against Gram-negative species.

    Common Pitfalls or Misconceptions

    • Azathramycin A is not suitable for direct clinical application due to instability and impurity status.
    • It is ineffective against most Gram-negative bacterial strains under standard conditions.
    • Long-term storage in dissolved form (>24 hours) leads to rapid degradation, especially at room temperature.
    • Its ribosome binding specificity is not universal; activity must be confirmed in the target species.
    • It should not be used as a substitute for Azithromycin in therapeutic protocols.

    Workflow Integration & Parameters

    Azathramycin A (SKU: BA1060) is supplied as a solid by APExBIO and should be stored at -20°C in a dry, light-protected environment. For use, dissolve in DMSO or ethanol at concentrations up to 52.8 mg/mL and 47.4 mg/mL, respectively. Avoid water as a solvent. Prepare working solutions fresh before each experiment. For ribosome binding and protein synthesis inhibition assays, use concentrations between 1–10 μM, incubate at 37°C, and maintain pH 7.4. Do not store diluted solutions longer than 24 hours (APExBIO).

    For advanced workflows in TB infection modeling and ribosomal inhibition studies, consult the latest methodologies in this visionary outlook article, which is complemented here with explicit solubility and storage constraints.

    Conclusion & Outlook

    Azathramycin A is a validated macrolide antibiotic and ribosome inhibitor of M. tuberculosis with well-defined parameters for research use. Its specificity and biophysical profile make it an essential tool for antibacterial mechanism elucidation, TB infection modeling, and resistance pathway studies. As research advances, Azathramycin A will remain central to workflows investigating ribosomal protein synthesis inhibition in tuberculosis, but its use is limited to controlled laboratory settings due to its instability and impurity status. For detailed parameters and procurement, refer to the APExBIO Azathramycin A product page.